Pages that link to "Q63241960"

The following pages link to Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? (Q63241960):

Displaying 26 items.

• Expression and functional analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 isozymes (Q24320062) (← links)
• A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine (Q24322097) (← links)
• Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response (Q28252209) (← links)
• Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders (Q34391577) (← links)
• Pharmacogenetic tactics and strategies: implications for paediatrics (Q34481324) (← links)
• The AmpliChip CYP450 genotyping test: Integrating a new clinical tool (Q34537662) (← links)
• Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry (Q35584152) (← links)
• Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study (Q35644151) (← links)
• Frequency of Undetected CYP2D6 Hybrid Genes in Clinical Samples: Impact on Phenotype Prediction (Q35647154) (← links)
• Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). (Q35826495) (← links)
• The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia (Q35827498) (← links)
• Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives (Q38631387) (← links)
• Genetics and psychopharmacology: prospects for individualized treatment. (Q36206096) (← links)
• Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants (Q36536465) (← links)
• Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance (Q36582619) (← links)
• Pharmacogenetics of opioids (Q36752672) (← links)
• CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. (Q38645783) (← links)
• Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose (Q42125291) (← links)
• Carvedilol Pharmacokinetics and Pharmacodynamics in Relation to CYP2D6 and ADRB Pharmacogenetics (Q42733745) (← links)
• Optimized Strategy for Rapid Cytochrome P450 2D6 Genotyping by Real-Time Long PCR (Q44590747) (← links)
• Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10 - A study on therapeutic drug monitoring data from 1,003 genotyped Scandinavian patients (Q57470487) (← links)
• Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions (Q61037225) (← links)
• Pharmacogenomics in Palliative Medicine (Q64093141) (← links)
• Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing (Q78760269) (← links)
• [Pharmacogenetics. Clinical relevance in anesthsiology] (Q86843930) (← links)
• Relationships between CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 metabolic phenotypes and genotypes in a Nicaraguan Mestizo population (Q100464871) (← links)